Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04589845 |
TitleTumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase
Phase 2
|
Date Added 2020-10-19 |
Location
Alabama, United States
Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Maine, United States Maryland, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Australia Belgium Brazil Canada China Denmark France Germany Hong Kong Israel Italy Japan New Zealand Poland Portugal Puerto Rico Singapore South Africa South Korea Spain Switzerland Taiwan United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03310008 |
TitleDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | Phase
Phase 1
|
Date Added 2017-10-16 |
Location
Belgium
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
NKR-2 cells |
Tags
MSS/ MMRp
|
| NCT ID NCT03984578 |
TitleWindow of Opportunity Study in Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-13 |
Location
Singapore
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04591431 |
TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | Phase
Phase 2
|
Date Added 2020-10-19 |
Location
Italy
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib |
Tags
MSS/ MMRp
|
| NCT ID NCT04009681 |
TitleA Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2019-07-05 |
Location
Arizona, United States
Colorado, United States Florida, United States Tennessee, United States Texas, United States Argentina Australia Chile Singapore Spain |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
anti-EGFR antibody, Checkpoint inhibitor, THOR-707 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02215889 |
TitlePartial Liver Segment 2/3 Transplantation Study | Phase
Phase 1
|
Date Added 2014-08-13 |
Location
Norway
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04130854 |
TitleINNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | Phase
Phase 2
|
Date Added 2019-10-18 |
Location
Arizona, United States
North Carolina, United States Oregon, United States Texas, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days |
Tags
MSS/ MMRp
|
| NCT ID NCT03921684 |
TitleTrial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | Phase
Phase 2
|
Date Added 2019-04-19 |
Location
Israel
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
capecitabine, mFOLFOX6, Nivolumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03475004 |
TitleStudy of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | Phase
Phase 2
|
Date Added 2018-03-23 |
Location
Colorado, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Bevacizumab, and Binimetinib |
Tags
MSS/ MMRp
|
| NCT ID NCT04940546 |
TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | Phase
Phase 1, Phase 2
|
Date Added 2021-06-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, capecitabine, oxaliplatin, Sintilimab |
Tags
MSS/ MMRp
|
